Kidney Transplant Failure and Rejection Clinical Trial
Official title:
ASSOCIATION OF miRNA WITH ALLOGRAFT FUNCTION AND EXPRESSION PROFILES PREDICTIVE OF DISEASES OCCURING AFTER KIDNEY TRANSPLANTATION
MicroRNAs (miRNAs) belong to a class of small non-coding RNAs that modulate physiological and
pathological processes by post-transcriptional regulation of gene expression mainly via
translational inhibition of target messenger RNAs. Recently, many miRNAs were found to be
involved in pathological processes that occur following kidney transplantation, like
allograft rejection, de novo disease or disease recurrence after kidney transplantation. As
most of the miRNAs involved in kidney diseases are extracted by urine, the diagnostic
accuracy of such molecules as biomarkers is questionable.
The aim of this study is to analyze expression of selected miRNAs (miR-29c, miR-126,
miR-146a, miR-150, miR-155, miR-223) and evaluate whether their regulation is associated with
kidney graft function and disease processes after kidney transplantation (KTx).
MicroRNAs (miRNA) are short, endogenous non-coding RNAs involved in the modulation of gene
expression mainly by inhibition of messenger RNAs translation. Recent studies have indicated
association of miRNAs with pathological processes following kidney transplantation.
The aim of the study is to determine whether selected miRNAs are related to specific disease
process or only reflect kidney graft function.
The study enrolled 100 Caucasian KTRs, who presented with stable renal function (as indicated
by stable serum creatinine (Cr) for 3 months and whose kidney graft function was thereafter
estimated with various methods, including: cystatin C concentration, three different CKD EPI
equations and measured with chromium-51 ethylenediamine tetraacetic acid clearance.
Expression of 6 selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, and miR-223)
was determined by qPCR using miRNA-103a, miR-191, and miR-423 as reference genes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04057742 -
AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
|
||
| Recruiting |
NCT03465397 -
Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients
|
Phase 4 | |
| Completed |
NCT03437577 -
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05282966 -
Assessment of QSant™ for Underlying Allograft Rejection
|
||
| Recruiting |
NCT04388930 -
The Microbiota in Kidney Donation and Transplantation
|
||
| Completed |
NCT03611621 -
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
|
||
| Recruiting |
NCT05397821 -
Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
|
||
| Completed |
NCT04019353 -
Cf-DNA Assay During Treatment of Acute Rejection
|
||
| Active, not recruiting |
NCT05806749 -
Immunological Tolerance in Patients With Mismatched Kidney Transplants
|
Phase 1 | |
| Recruiting |
NCT04936282 -
Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)
|
Phase 4 | |
| Enrolling by invitation |
NCT05285878 -
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
|
Phase 2 | |
| Recruiting |
NCT04526431 -
Tacrolimus Pharmacokinetic Subpopulations
|
||
| Active, not recruiting |
NCT03511560 -
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
|
Phase 4 | |
| Recruiting |
NCT03438773 -
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
|
Phase 1 | |
| Completed |
NCT05388955 -
Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
|
||
| Completed |
NCT06394596 -
Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
|
||
| Completed |
NCT03466775 -
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
|
N/A | |
| Active, not recruiting |
NCT04733131 -
Long-term Outcomes After Conversion to Belatacept
|
||
| Active, not recruiting |
NCT03380962 -
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04154267 -
Protocol Biopsies in High-risk Renal Transplant Recipients
|
N/A |